DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer

Information source: University Health Network, Toronto
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Esophageal Cancer

Intervention: Irinotecan (Drug); Cisplatin (Drug); Radiation (Procedure); Surgery (Procedure); sunitinib (Sutent) (Drug)

Phase: Phase 2

Status: Active, not recruiting

Sponsored by: University Health Network, Toronto

Official(s) and/or principal investigator(s):
Jennifer J Knox, MD M.Sc. FRCPC, Principal Investigator, Affiliation: University Health Network, Toronto


The purpose of this study is to see whether or not the combination of cisplatin, irinotecan and radiation, followed by surgery, followed by oral Sutent, is effective and safe for patients with resectable esophageal cancer.

Clinical Details

Official title: Adjuvant Sutent Following Chemotherapy, Radiation and Surgery For Esophageal Cancer, A Phase II Trial (ASSET)

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: To determine the feasibility and efficacy of adjuvant Sutent therapy after concurrent neoadjuvant therapy with Irinotecan, Cisplatin, external beam conformal radiotherapy plus surgery for potentially resectable esophageal cancer.

Secondary outcome:

To assess the impact of adjuvant targeted therapy with Sutent after multimodality therapy for resected esophageal cancer stage II to III, and to compare these data to our current completed trial in the same patient population

To characterize toxicity of targeted adjuvant therapy with Sutent after multimodality therapy for resected esophageal cancer stage II to III

To measure time-to-event efficacy variables including: Time to treatment failure and Time to progressive disease

Survival of patients with esophageal cancer stage II to III with adjuvant targeted therapy added to multimodality treatment protocol

To determine the pattern of relapse (local versus distant) with the addition of adjuvant targeted therapy to esophageal cancer multimodality therapy

Detailed description: Survival outcomes for resectable esophageal cancer remain poor. Current data strongly support an adjuvant systemic strategy to improve time to progression and survival in this patient population. Adding a well-tolerated oral targeted therapy such as Sutent, after a combined chemo/radiation/surgery approach in this patient population has the potential to impact on the minimal residual disease left behind by relatively effective pre-operative chemoradiation and surgery. This has the potential to improve survival. The primary endpoint is to determine the feasibility and efficacy of adjuvant Sutent therapy (SU11248) after concurrent neoadjuvant therapy with irinotecan, cisplatin, external beam conformal radiotherapy plus surgery for potential resectable esophageal cancer. Preclinical and clinical data suggest that Sutent will have activity in esophageal cancer, as the results of Sutent activity in solid tumors appear to be superior to the results of other antiangiogenic compounds in development for esophageal cancer. Therefore, by extrapolation from promising phase I, II and III Sutent trials we propose to translate the target effects achieved with Sutent to reduce local and systemic therapy failure, and thus metastasis in esophageal cancer.


Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Both.


Inclusion Criteria:

- Histologically proven squamous or adenocarcinoma or the esophagus >20 cm from the

incisors, including GE junction tumors (unless of gastric origin).

- Tumors must be technically resectable.

- Clinical T1N1M0, T2-3 N0-1 M0

- Performance status ECOG 0-1

- Medically fit for chemotherapy, radiation and esophagectomy

Exclusion Criteria:

- In situ or clinical T1N0M0, and stage IV (M1a orM1b)

- Cervical esophageal tumors (within 20 cm of the incisors)

- Age <18 or >70

- Participation in another concurrent clinical study involving study drug(s) or

treatment with study drug within thirty days prior to the treatment on this study. Concurrent treatment with other experimental drugs or anticancer therapy

- known or suspected drug or alcohol abuse

- Prior treatment for this malignancy except esophageal stenting

Locations and Contacts

The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario K1H 8L6, Canada

University Health Network (Princess Margaret & Toronto General Hospitals), Toronto, Ontario M5G 2C4, Canada

Additional Information

Starting date: November 2006
Last updated: September 9, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017